SAN FRANCISCO (
(CELG - Get Report)
was a big winner on the first day of the J.P. Morgan Healthcare Conference.
The big-cap biotech is the traditional kick-off presentation at this closely followed conference, and this year, the company set a high bar for its competitors with strong financial guidance (including a bullish 2017 forecast for the first time) and positive psoriasis results from studies involving its experimental drug apremilast.
Celgene shares rose more than 4% to $85.73 on Monday and the stock was up again in Tuesday's pre-market session, bolstered by some analyst upgrades.
(GILD - Get Report)
(BIIB - Get Report)
also presented at the J.P. Morgan conference on Monday. While both offered confident outlooks for the coming year, Celgene was a standout.
(AMGN - Get Report)
presents at the conference later today.
Read a lot more about Celgene's outlook and the way
investors and others reacted to the company's J.P. Morgan presentation
on Twitter with this Appeering
-- Reported by Adam Feuerstein in Boston.
Follow Adam Feuerstein on